4.7 Article

Angiopoietin-2 impairs revascularization after limb ischemia

期刊

CIRCULATION RESEARCH
卷 101, 期 1, 页码 88-96

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.106.143594

关键词

angiopoietins; Tie2; collateral artery growth; hindlimb ischemia; angiopoietin transgenic mice

向作者/读者索取更多资源

Angiopoietins play important roles in the formation of neovessels and complex vascular networks. Angiopoietin ( Ang)- 1 and Ang- 2 belong to a family of growth factors that display opposing effects on the activation of Tie2 ( tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2). Endothelial Ang- 2 expression is associated with vessel destabilization and regulates a balance between vascular regression and growth. To elucidate, in particular, the role of Ang- 2 after arterial artery occlusion in the mouse limb, we applied a transgenic animal model with targeted Ang- 2 expression in endothelial cells. We show here that restoration of blood flow in Ang- 2: Tie1 transgenic mice is dramatically impaired when Ang- 2 expression is induced in the vasculature. The defective restoration of perfusion in Ang- 2 transgenic mice is evidenced by reduced collateral artery growth, which typically occurs to compensate for flow deficits after occlusion of the large conductance artery. Furthermore, reduced movement capacities and higher incidents of necrosis are consequently observed in the transgenic limbs as compared with controls. Mechanistically, the observed effects are attributed to defective smooth muscle cell recruitment in Ang- 2 transgenic mice. Moreover, distinct Ang- 2 levels in the genetically modified animals clearly correlated with the magnitude of reduced perfusion. In conclusion, our studies define Ang- 2 as an important molecule for the progression of collateral artery growth and angiogenesis during ischemia and suggest precise Ang- 2 dosage activities to accomplish blood vessel growth.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据